This Article Full Text Full Text (PDF) All Versions of this Article: 92/7/2844    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Carette, C. Articles by Bellanné-Chantelot, C. Search for Related Content PubMed PubMed Citation Articles by Carette, C. Articles by Bellanné-Chantelot, C. Related Collections Diabetes and Insulin

Exonic Duplication of the Hepatocyte Nuclear Factor-1ß Gene (Transcription Factor 2, Hepatic) as a Cause of Maturity Onset Diabetes of the Young Type 5

Department of Immunology and Diabetology (C.C., J.T.), Université René Descartes Paris 5, AP-HP Hôpital Cochin, F-75014 Paris, France; Department of Molecular Biology (C.V., S.C.), AP-HP Hôpital Saint Antoine, F-75012 Paris, France; Department of Pediatry (A.B.), Centre Hospitalier Général de Montelimar, F-26216 Montelimar, France; Department of Nephrology (J.-P.G.), AP-HP Hôpital Necker Enfants Malades, F-75015 Paris, France; and Department of Cytogenetics (C.B.-C.), AP-HP Hôpital Saint Antoine, Université Pierre et Marie Curie Paris 6, F-75012 Paris, France

Address all correspondence and requests for reprints to: Claire Carette, Service d’Immunologie-Diabétologie, 27 rue du Faubourg Saint Jacques, Hôpital Cochin, 75014 Paris, France. E-mail: claire.carette{at}cch.aphp.fr.

Context: Maturity onset diabetes of the young (MODY) type 5 has been described as the association of early-onset diabetes and renal disease. Actually, MODY5 encompasses multiple phenotypes, including nondiabetic progressive renal failure, kidney and genital tract malformations, atypical familial hyperuricemic nephropathy, pancreas atrophy, and liver test abnormalities. The occurrence of MODY5 has been associated with various molecular abnormalities of TCF2, including missense, nonsense, small insertion/deletions, and splice site mutations, as well as large genomic deletions or single exonic deletion of TCF2.

Design: Using quantitative multiplex PCR amplification of short fluorescent fragments, we have analyzed the TCF2 gene in a French family of which three relatives presented a MODY5 phenotype. The proband had an extended clinical phenotype, including hyperuricemic nephropathy and early gout, chronic renal failure, renal morphological abnormalities, abnormal liver tests, and diabetes. His son had almost no clinical expression of the disease, whereas his grandson had a restricted but severe renal phenotype present from birth.

Results: We show that a duplication of the exon 5 of TCF2 is responsible for the MODY5 phenotypes in this family.

Conclusions: Thus, we describe a novel molecular mechanism that may be responsible for MODY5, and we emphasize the wide intrafamilial variability of MODY5 expressivity. These observations suggest that the diagnosis of MODY5 may be raised even in subjects with partial phenotypes. They also confirm that quantitative multiplex PCR amplification of short fluorescent fragments analysis should be the first step of genetic screening in patients with a MODY5 phenotype.